TME PHARMA
TME Pharma is a biopharmaceutical company, develops biostable aptamers and substances based on mirror image nucleic acids. Its Spiegelmer is a mirror image oligonucleotide therapeutic for the pharmacologically relevant target. The company has a strategic alliance with Pfizer, Inc. NOXXON Pharma AG was founded in 1997 and is based in Berlin, Germany.
TME PHARMA
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1998-01-01
Address:
Berlin, Berlin, Germany
Country:
Germany
Website Url:
http://www.tmepharma.com
Total Employee:
51+
Status:
Active
Contact:
49 30 72 62 47 0
Total Funding:
138.73 M EUR
Technology used in webpage:
Domain Not Resolving SPF Cloudflare Hosting Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS YouTube
Similar Organizations
4D Pharma
4D Pharma PLC is a world leader in the development of live biotherapeutics.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Atlas Venture
Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
BionPharma
BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships.
Radius Health
Radius Health develops drug therapies for osteoporosis and women’s health.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Atlas Special Opportunities
Atlas Special Opportunities investment in Post-IPO Debt - TME Pharma
Atlas Special Opportunities
Atlas Special Opportunities investment in Post-IPO Debt - TME Pharma
Kreos Capital
Kreos Capital investment in Post-IPO Equity - TME Pharma
Atlas Special Opportunities
Atlas Special Opportunities investment in Post-IPO Debt - TME Pharma
Acuitas Investments
Acuitas Investments investment in Post-IPO Equity - TME Pharma
Kreos Capital
Kreos Capital investment in Post-IPO Debt - TME Pharma
Andera Partners
Andera Partners investment in Series D - TME Pharma
TVM Capital
TVM Capital investment in Series D - TME Pharma
bmp Ventures
bmp Ventures investment in Series D - TME Pharma
Dow Venture Capital
Dow Venture Capital investment in Series D - TME Pharma
Official Site Inspections
http://www.tmepharma.com Semrush global rank: 4.25 M Semrush visits lastest month: 2.33 K
- Host name: 217-160-0-165.elastic-ssl.ui-r.com
- IP address: 217.160.0.165
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "TME Pharma"
TME Pharma - About
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor …See details»
TME Pharma
2024, April 25 06:00 p.m. TME Pharma publishes 2023 financial results and provides operating update 2024, April 23 08:00 a.m. TME Pharma announces 33% of patients receiving NOX-A12 …See details»
TME Pharma - Wikipedia
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris (ALTME)and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa). See details»
TME Pharma - LinkedIn
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment...See details»
TME Pharma N.V. - healthtechinnovationdays6.com
HealthTech For Care is an endowment fund (non-for profit organization) whose primary mission is to advocate for universal access to healthcare for all European patients, with a specific focus …See details»
TME Pharma: Contact Details and Business Profile
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor …See details»
TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor …See details»
TME Pharma Announces Further Improvement in Median Overall …
Dec 20, 2023 · TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor …See details»
October 2024 - TME Pharma
Utic impact. TME Pharma’s mission is to improve treatment outcomes for patients with cancer where the tumor microenvironment significantly lim. ts survival. The lead compound NOX-A12 …See details»
TME Pharma - VentureRadar
Website: https://www.tmepharma.com/ TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in …See details»
TME Pharma Company Profile - Office Locations, Competitors
Oct 28, 2024 · TME Pharma (formerly known as NOXXON Pharma) is a clinical-stage biopharmaceutical company that focuses on the development of proprietary therapeutics for …See details»
TME Pharma - Overview, News & Similar companies | ZoomInfo.com
Nov 28, 2022 · TME Pharma contact info: Phone number: +49 307262470 Website: www.tmepharma.com What does TME Pharma do? Headquartered in Berlin, Germany, TME …See details»
TME Pharma Announces Results of Successful Capital Increase …
Dec 14, 2023 · TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor …See details»
NOXXON Pharma Announces Name Change to “TME Pharma” and …
Jul 15, 2022 · TME Pharma N.V., a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced …See details»
Improving Therapeutic Outcomes by Targeting the Tumor …
5 Median Overall Survival (mOS) 9.5 months n = 22 12.7 months 19.9 months Sources: Giordano (2022) ASCO Annual Meeting Presentation #2050; Giordano (2022) SNO Annual Meeting …See details»
TME Pharma Announces Successful Advice Meeting With US Food …
Jan 9, 2024 · TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company’s oncology-focused pipeline is …See details»
TME Pharma Announces Strategic Plan to Externalize and …
Jul 22, 2024 · TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor …See details»
TME PHARMA PUBLISHES AUDITED ANNUAL REPORT 2022
ME Pharma in July 2022. TME Pharma continues to work on the same clinical programs as NOXXON and aims to develop and commercialize its proprietary class of drugs called …See details»
Breaking Barriers in Cancer Treatment: TME Pharma Secures $2.4 …
As a clinical-stage company, TME Pharma is dedicated to developing innovative therapies that target the tumor microenvironment (TME), a critical area of focus that has the potential to …See details»
NOXXON PHARMA ANNOUNCES NAME CHANGE TO “TME …
TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company’s oncology-focused pipeline is designed to act on …See details»